YouJizz porno atasehir escort bostanci escort erenkoy escort goztepe escort kadikoy Escort kartal Escort maltepe Escort suadiye Escort uskudar Escort umraniye Escort kartal escort bostanci escort atasehir escort kadikoy escort kurtkoy escort tuzla escort erenkoy escort beykoz escort umraniye escort pendik escort kadikoy escort maltepe escort antalya escort konya escort

Market Research Reports and Industry Reports

Adherence What Do Pharma Really Know

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Adherence – What Do Pharma Really Know
The entire industry is talking about patient centricity but are the right steps being taken to address the most fundamental patient issue: non-adherence? Is ‘big brother’ technology the answer? Perhaps education is the key? What can be done to ensure patients take drugs as they are intended to be taken and reap the benefits accordingly?

Adherence: What do pharma really know? explores the main issues including physician impact, the variety of factors leading to non-adherence, and the potential solutions and pitfalls. Find out what leading industry experts say, not only about the important issues but also about the crucial actions and strategies that lead to success.

Discover on this page…

The executive summary below, taken directly from the report, presents key findings from the research
The rigorous research objectives and methodologies employed to produce the report
Detailed report contents
Why this report is important to you

Executive Summary

In the context of pharmaceuticals, patient adherence is a metric that can best be defined as the way in which patients take their medications as prescribed by a physician. For example, good patient adherence includes taking the correct dosage of a medication for the full duration of treatment.


Non-adherence, whereby a patient fails to take their medication as recommended or prescribed, can have a significant impact on patient outcomes. It also has a considerable financial cost to both the pharmaceutical companies, who lose revenue if patients do not persist with their medication, and the healthcare system, which bears the cost of the consequences of non-adherence, such as hospitalisations and additional medical interventions. Further, physicians may be negatively impacted as the non-adherence can be perceived as a patient not responding to therapy in the way they expect, which can in turn affect the physician’s confidence in a medication, as well as physicians being required to provide additional management of non-responsive patients.


Pharmaceutical companies have invested significant time and resource into understanding reasons for non-adherence, patient and healthcare provider education and support programmes to promote consistent adherence. These have met with varied success – for those patients who are non-intentionally non-adherent, support programmes and reminder services can be very beneficial as they address the core reason for this non-adherence; forgetting to take their medication as intended. In contrast, simple reminders and support programmes do not have the same impact for patients who are intentionally non-adherent, actively deciding not to take their medication due to a range of factors including fear of side effects, affordability issues, lack of education about the drug and the complexity of the regimen. Instead, adherence interventions are more focused on changing behaviour, through education programmes or, increasingly, through interactive technology that allows healthcare providers and carers to monitor the patients’ adherence and proactively take steps to address failure to take their medication.


As adherence support offerings have become more sophisticated, through the use of advanced technology, tailored adherence support is becoming more common with pharmaceutical companies increasingly offering individualised experiences that appeal to each different customer. Technology such as wearables and smartphones have closed the loop in providing feedback on how patients are taking their medication and, in addition to enabling healthcare providers to be proactive in managing their patients’ health, these technologies provide pharmaceutical companies with an invaluable source of robust data. Indeed, some companies are collecting outcomes data in this way and using this information to show how a particular product would deliver greater benefits to patients, physicians and payers compared to competitor drugs.


This report will examine the growing importance of adherence to pharmaceutical companies and the strategies that are being implemented to address the drivers of non-adherence amongst patients. It will assess the different factors that contribute to non-adherence, the activities that pharmaceutical companies are undertaking to tackle non-adherence and how these are expected to evolve with the growing use of technology. The report will also provide insight into the way in which companies’ design and implement adherence support programmes and how the creation of specific patient solutions teams is impacting on adherence strategies.

Research Methodology and Objectives

This report provides insight into the evolving area of adherence in the context of patient-centricity and added value strategies. It also offers guidance on how to steer your adherence strategies towards successful results.

Analysis is based on in depth interviews with seven senior experts, each of whom have extensive experience of adherence and patient programmes.

Git Patel, CEO Sargas Pharmaceutical Adherence & Compliance (SPAC) International
Soren E Skovlund, Senior Researcher, People Centered HealthCare and Lead on Patient Reported Outcomes, Faculty of Health Sciences, Aalborg University. Chief Patient Officer at DrugStars Inc
Sinead Tuite, Patient Programmes Manager, MSD
Jason DeGoes, Head of Global Patient Solutions Team at Teva Pharmaceuticals
Marketing Head, Global Vaccines Company
Former Global Patient Adherence Lead at Novartis Pharmaceuticals
Director, Global Patient Solutions Lead

Key questions explored in this report include

What is the latest thinking regarding intentional and unintentional non-adherence?
What are the range of factors leading to non-adherence?
Why is adherence so important to all stakeholders and what is its impact?
What more can be done to support patient and physician education as a route to addressing non-adherence?
What should a successful adherence programme look like? What specific elements are crucial?
Is technology the key to success? How can technological developments be better utilised to address non-adherence?

How do companies address adherence?

Key insights

Pharmaceutical companies are addressing adherence through a range of initiatives

Understanding the behaviour that drives non-adherence is critical
Physician and patient education is a critical part of promoting adherence
Redesigning medication packaging and devices can help promote greater adherence
Support programmes are the mainstay of adherence strategies
Physicians tend to over-estimate the level of adherence
Intentional non-adherence can be difficult to tackle
Internal challenges can limit a company’s commitment to addressing adherence

Pharmaceutical companies are starting to focus resource on adherence

Key insights
Adherence has traditionally been the responsibility of the brand team but this is changing
Companies use a range of insights to design and implement adherence programmes
External stakeholder input is critically important
A range of internal stakeholders will be involved in adherence programmes
The rise in demand and diversity of stakeholders is creating new challenges
A successful adherence programme should be designed at an early stage
It can be difficult to engage with HCPs on adherence programmes
Measuring adherence programmes can be challenging

The future for adherence

Key insights
Adherence should become an integral part of product strategy
A deep understanding of behaviour and psychology will drive adherence programme design
Technology will be employed to a greater degree
Tailored adherence solutions will become more important
Companies must dedicate sufficient time and resource to adherence and support programmes


Why this report is important to you

As part of the package of change underway across the industry, adherence has an important role to play. We’re experiencing multiple developments including intense downward cost pressure, the push towards patient centricity, greater demand for added value, rapidly evolving technologies and the quest for evidence based outcomes. With this backdrop, the evolution of effective, results-oriented adherence programmes is a logical and inevitable development – but we’re not there yet.

Physicians continue to overestimate adherence levels and payers are not yet shouting loudly enough for the industry to make the significant investment needed to solve this issue. In the meantime, the opportunity remains. Pharma and patients will reap the benefits when, not if, more effective solutions to non-adherence take hold. Only then will the tide begin to turn.

This report will enable you to…

Understand why adherence solutions are now more patient-centric
Review the commercial arguments for an effective adherence programme
Find out more about the initiatives already being undertaken to tackle non-adherence
Discover how successful adherence support programmes are designed and implemented
Gain insight into the evolving role of patient-centric teams
Learn about new methods of measuring adherence
Plan ahead for the key trends expected to impact future adherence programmes

1. Executive Summary
2. Research Objectives and Methodology
3. Adherence overview
3.1 Key Insights
3.2 What is adherence?
3.2.1 Adherence is evolving to be seen as more patient-centric
3.3 Adherence is critically important for all stakeholders
3.3.1 Patient outcomes are adversely impacted by non-adherence
3.3.2 There is a considerable commercial impact of non-adherence
3.3.3 Non-adherence has a significant financial cost
3.4 The level of adherence can vary across patient populations
3.4.1 The treatment goal exerts an impact on adherence
3.5 A range of factors lead to non-adherence
3.5.1 Physicians have a critical role to play in patient adherence
3.5.2 Non-intentional non-adherence tends to be an area that pharmaceutical companies focus on
3.5.3 Patient knowledge and beliefs are a key driver of non-adherence
4. How do companies address adherence?
4.1 Key Insights
4.2 Pharmaceutical companies are addressing adherence through a range of initiatives
4.2.1 Understanding the behaviour that drives non-adherence is critical
4.2.2 Physician and patient education is a critical part of promoting adherence
4.2.3 Redesigning medication packaging and devices can help promote greater adherence
4.2.4 Support programmes are the mainstay of adherence strategies
4.3 There are several challenges with monitoring and driving adherence
4.3.1 Physicians tend to over-estimate the level of adherence
4.3.2 Intentional non-adherence can be difficult to tackle
4.3.3 Internal challenges can limit a company’s commitment to addressing adherence
5. Pharmaceutical companies are starting to focus resource on adherence
5.1 Key Insights
5.2 Adherence has traditionally been the responsibility of the brand team but this is changing
5.3 Companies use a range of insights to design and implement adherence programmes
5.3.1 External stakeholder input is critically important
5.3.2 A range of internal stakeholders will be involved in adherence programmes
5.3.3 The rise in demand and diversity of stakeholders is creating new challenges
5.4 A successful adherence programme should be designed at an early stage
5.5. It can be difficult to engage with HCPs on adherence programmes
5.6 Measuring adherence programmes can be challenging
6. The future for adherence
6.1 Key Insights
6.2 Adherence should become an integral part of product strategy
6.3 A deep understanding of behaviour and psychology will drive adherence programme design
6.4 Technology will be employed to a greater degree
6.4.1 Tailored adherence solutions will become more important
6.5 Companies must dedicate sufficient time and resource to adherence and support programmes


List Of Figures

Table 1: Three examples of the effect of non-adherence on treatment outcomes
Table 2: Revenue loss by major pharmaceutical class
Table 3: The Five Interacting Dimensions of Adherence
Figure 1: The Z-pak
Figure 2: The Humira pen and pre-filled syringe
Figure 3: Example of a text reminder and request for confirmation
Figure 4: The AlarMeds adherence and monitoring app
Figure 5: The imedipac
Figure 6: Challenges to monitoring and driving adherence
Figure 7: SWOT analysis of adherence offerings provided by pharmaceutical companies
Figure 8: Who funds and initiates adherence programmes in your organisation? 
Figure 9: Different methods of measuring adherence


Global Medication Adherence Packaging Systems Market Size, Status and Forecast 2022

This report studies the Medication Adherence Packaging market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the

USD 3300View Report

Asia-Pacific Adherence Monitoring Cap Market Report 2017

In this report, the Asia-Pacific Adherence Monitoring Cap market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 695
  • Enterprise Wide Licence    USD 5650
$ 695

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube